Immunohistochemical detection of BCL-3 in lymphoid neoplasms

A survey of 353 cases

Ozlem Canoz, George Z. Rassidakis, Joan Admirand, L. Jeffrey Medeiros

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The bcl-3 gene at chromosome 19q13 encodes a member of the IκB family involved in regulating the NFκB pathway. Originally identified by its involvement in the rare t(14:19)(q32;q13), BCL-3 expression has never been analyzed in a wide variety of lymphomas. We assessed BCL-3 expression in 353 cases of non-Hodgkin lymphoma and Hodgkin lymphoma using formalin-fixed, paraffin-embedded tissue specimens, a monoclonal antibody specific for BCL-3, and immunohistochemical methods. Of 172 B-cell lymphomas, 10 (6%) were positive for BCL-3, including six of 23 (26%) diffuse large B-cell lymphoma, one of 17 (6%) small lymphocytic lymphoma, one of 26 (4%) follicular lymphoma, and two of 49 (4%) mantle cell lymphoma. All other B-cell neoplasms were negative, including marginal zone lymphoma (n=24, 11 extranodal, nine nodal, four splenic), Burkitt lymphoma (n=10), lymphoplasmacytic lymphoma (n=10), lymphoblastic lymphoma (n=8), and plasmacytoma (n=5). Of 111 T/NK-cell lymphomas, 25 (23%) were positive for BCL-3, including 13 of 40 (32%) anaplastic large-cell lymphoma, three of 10 (30%) angioimmunoblastic T-cell lymphoma, two of eight (25%) extranodal NK/T-cell lymphoma of nasal type, three of 12 (25%) mycosis fungoides, one of five (20%) enteropathy-type T-cell lymphoma, and two of 21 (10%) peripheral T-cell lymphoma unspecified. All other T-cell neoplasms were negative, including lymphoblastic lymphoma (n=6), prolymphocytic leukemia (n=6), and subcutaneous panniculitis-like T-cell lymphoma (n=3). Of 70 Hodgkin lymphomas, of all types, 29 (41%) were positive for BCL-3. The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin lymphoma types raises the possibility that BCL-3 is involved in the pathogenesis of these tumors, and may be a target of new therapies.

Original languageEnglish (US)
Pages (from-to)911-917
Number of pages7
JournalModern Pathology
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2004

Fingerprint

T-Cell Lymphoma
Hodgkin Disease
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma
Extranodal NK-T-Cell Lymphoma
Prolymphocytic Leukemia
Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Mantle-Cell Lymphoma
Neoplasms
Mycosis Fungoides
Follicular Lymphoma
Plasmacytoma
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Natural Killer Cells
Paraffin

Keywords

  • BCL-3
  • Hodgkin lymphoma
  • Immunohistochemistry
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Immunohistochemical detection of BCL-3 in lymphoid neoplasms : A survey of 353 cases. / Canoz, Ozlem; Rassidakis, George Z.; Admirand, Joan; Medeiros, L. Jeffrey.

In: Modern Pathology, Vol. 17, No. 8, 01.08.2004, p. 911-917.

Research output: Contribution to journalArticle

Canoz, Ozlem ; Rassidakis, George Z. ; Admirand, Joan ; Medeiros, L. Jeffrey. / Immunohistochemical detection of BCL-3 in lymphoid neoplasms : A survey of 353 cases. In: Modern Pathology. 2004 ; Vol. 17, No. 8. pp. 911-917.
@article{b9e25f879a8b4241a7c75471b3633600,
title = "Immunohistochemical detection of BCL-3 in lymphoid neoplasms: A survey of 353 cases",
abstract = "The bcl-3 gene at chromosome 19q13 encodes a member of the IκB family involved in regulating the NFκB pathway. Originally identified by its involvement in the rare t(14:19)(q32;q13), BCL-3 expression has never been analyzed in a wide variety of lymphomas. We assessed BCL-3 expression in 353 cases of non-Hodgkin lymphoma and Hodgkin lymphoma using formalin-fixed, paraffin-embedded tissue specimens, a monoclonal antibody specific for BCL-3, and immunohistochemical methods. Of 172 B-cell lymphomas, 10 (6{\%}) were positive for BCL-3, including six of 23 (26{\%}) diffuse large B-cell lymphoma, one of 17 (6{\%}) small lymphocytic lymphoma, one of 26 (4{\%}) follicular lymphoma, and two of 49 (4{\%}) mantle cell lymphoma. All other B-cell neoplasms were negative, including marginal zone lymphoma (n=24, 11 extranodal, nine nodal, four splenic), Burkitt lymphoma (n=10), lymphoplasmacytic lymphoma (n=10), lymphoblastic lymphoma (n=8), and plasmacytoma (n=5). Of 111 T/NK-cell lymphomas, 25 (23{\%}) were positive for BCL-3, including 13 of 40 (32{\%}) anaplastic large-cell lymphoma, three of 10 (30{\%}) angioimmunoblastic T-cell lymphoma, two of eight (25{\%}) extranodal NK/T-cell lymphoma of nasal type, three of 12 (25{\%}) mycosis fungoides, one of five (20{\%}) enteropathy-type T-cell lymphoma, and two of 21 (10{\%}) peripheral T-cell lymphoma unspecified. All other T-cell neoplasms were negative, including lymphoblastic lymphoma (n=6), prolymphocytic leukemia (n=6), and subcutaneous panniculitis-like T-cell lymphoma (n=3). Of 70 Hodgkin lymphomas, of all types, 29 (41{\%}) were positive for BCL-3. The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin lymphoma types raises the possibility that BCL-3 is involved in the pathogenesis of these tumors, and may be a target of new therapies.",
keywords = "BCL-3, Hodgkin lymphoma, Immunohistochemistry, Non-Hodgkin lymphoma",
author = "Ozlem Canoz and Rassidakis, {George Z.} and Joan Admirand and Medeiros, {L. Jeffrey}",
year = "2004",
month = "8",
day = "1",
doi = "10.1038/modpathol.3800140",
language = "English (US)",
volume = "17",
pages = "911--917",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Immunohistochemical detection of BCL-3 in lymphoid neoplasms

T2 - A survey of 353 cases

AU - Canoz, Ozlem

AU - Rassidakis, George Z.

AU - Admirand, Joan

AU - Medeiros, L. Jeffrey

PY - 2004/8/1

Y1 - 2004/8/1

N2 - The bcl-3 gene at chromosome 19q13 encodes a member of the IκB family involved in regulating the NFκB pathway. Originally identified by its involvement in the rare t(14:19)(q32;q13), BCL-3 expression has never been analyzed in a wide variety of lymphomas. We assessed BCL-3 expression in 353 cases of non-Hodgkin lymphoma and Hodgkin lymphoma using formalin-fixed, paraffin-embedded tissue specimens, a monoclonal antibody specific for BCL-3, and immunohistochemical methods. Of 172 B-cell lymphomas, 10 (6%) were positive for BCL-3, including six of 23 (26%) diffuse large B-cell lymphoma, one of 17 (6%) small lymphocytic lymphoma, one of 26 (4%) follicular lymphoma, and two of 49 (4%) mantle cell lymphoma. All other B-cell neoplasms were negative, including marginal zone lymphoma (n=24, 11 extranodal, nine nodal, four splenic), Burkitt lymphoma (n=10), lymphoplasmacytic lymphoma (n=10), lymphoblastic lymphoma (n=8), and plasmacytoma (n=5). Of 111 T/NK-cell lymphomas, 25 (23%) were positive for BCL-3, including 13 of 40 (32%) anaplastic large-cell lymphoma, three of 10 (30%) angioimmunoblastic T-cell lymphoma, two of eight (25%) extranodal NK/T-cell lymphoma of nasal type, three of 12 (25%) mycosis fungoides, one of five (20%) enteropathy-type T-cell lymphoma, and two of 21 (10%) peripheral T-cell lymphoma unspecified. All other T-cell neoplasms were negative, including lymphoblastic lymphoma (n=6), prolymphocytic leukemia (n=6), and subcutaneous panniculitis-like T-cell lymphoma (n=3). Of 70 Hodgkin lymphomas, of all types, 29 (41%) were positive for BCL-3. The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin lymphoma types raises the possibility that BCL-3 is involved in the pathogenesis of these tumors, and may be a target of new therapies.

AB - The bcl-3 gene at chromosome 19q13 encodes a member of the IκB family involved in regulating the NFκB pathway. Originally identified by its involvement in the rare t(14:19)(q32;q13), BCL-3 expression has never been analyzed in a wide variety of lymphomas. We assessed BCL-3 expression in 353 cases of non-Hodgkin lymphoma and Hodgkin lymphoma using formalin-fixed, paraffin-embedded tissue specimens, a monoclonal antibody specific for BCL-3, and immunohistochemical methods. Of 172 B-cell lymphomas, 10 (6%) were positive for BCL-3, including six of 23 (26%) diffuse large B-cell lymphoma, one of 17 (6%) small lymphocytic lymphoma, one of 26 (4%) follicular lymphoma, and two of 49 (4%) mantle cell lymphoma. All other B-cell neoplasms were negative, including marginal zone lymphoma (n=24, 11 extranodal, nine nodal, four splenic), Burkitt lymphoma (n=10), lymphoplasmacytic lymphoma (n=10), lymphoblastic lymphoma (n=8), and plasmacytoma (n=5). Of 111 T/NK-cell lymphomas, 25 (23%) were positive for BCL-3, including 13 of 40 (32%) anaplastic large-cell lymphoma, three of 10 (30%) angioimmunoblastic T-cell lymphoma, two of eight (25%) extranodal NK/T-cell lymphoma of nasal type, three of 12 (25%) mycosis fungoides, one of five (20%) enteropathy-type T-cell lymphoma, and two of 21 (10%) peripheral T-cell lymphoma unspecified. All other T-cell neoplasms were negative, including lymphoblastic lymphoma (n=6), prolymphocytic leukemia (n=6), and subcutaneous panniculitis-like T-cell lymphoma (n=3). Of 70 Hodgkin lymphomas, of all types, 29 (41%) were positive for BCL-3. The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin lymphoma types raises the possibility that BCL-3 is involved in the pathogenesis of these tumors, and may be a target of new therapies.

KW - BCL-3

KW - Hodgkin lymphoma

KW - Immunohistochemistry

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=3342964254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342964254&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800140

DO - 10.1038/modpathol.3800140

M3 - Article

VL - 17

SP - 911

EP - 917

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 8

ER -